Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Eli Lilly, Pfizer Halt Program for Osteoarthritis Pain Drug

10/26/2021 | 09:11am EST


ę MT Newswires 2021
All news about ELI LILLY AND COMPANY
12/01Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment C..
PR
11/30US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
MT
11/30CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
MT
11/30Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
MT
11/30MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..
MT
11/30Regeneron's COVID-19 antibody drug may be less effective against Omicron
RE
11/24Truist Securities Adjusts Eli Lilly and Co.'s Price Target to $301 from $262, Keeps Buy..
MT
11/19BMO Capital Starts Eli Lilly at Outperform With $311 Price Target
MT
11/18Emgality Versus Nurtec ODT Head-To-Head Migraine Preventive Treatment Study Now Enrolli..
CI
11/18Fountain Therapeutics, Inc. announced that it has received $15 million in funding from ..
CI
More news
Analyst Recommendations on ELI LILLY AND COMPANY
More recommendations
Financials (USD)
Sales 2021 27 480 M - -
Net income 2021 6 130 M - -
Net Debt 2021 12 164 M - -
P/E ratio 2021 37,0x
Yield 2021 1,32%
Capitalization 226 B 226 B -
EV / Sales 2021 8,66x
EV / Sales 2022 8,46x
Nbr of Employees 35 000
Free-Float 99,8%
Chart ELI LILLY AND COMPANY
Duration : Period :
Eli Lilly and Company Technical Analysis Chart | LLY | US5324571083 | MarketScreener
Technical analysis trends ELI LILLY AND COMPANY
Short TermMid-TermLong Term
TrendsNeutralNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 21
Last Close Price 249,13 $
Average target price 273,42 $
Spread / Average Target 9,75%
EPS Revisions
Managers and Directors
David A. Ricks Chairman, President & Chief Executive Officer
Anat Ashkenazi Chief Financial Officer & Senior Vice President
Timothy J. Garnett Chief Medical Officer & VP-Global Medical
Daniel M. Skovronsky Chief Scientific Officer & Senior Vice President
Diogo Rau Senior VP, Chief Information & Digital Officer
Sector and Competitors
1st jan.Capi. (M$)
ELI LILLY AND COMPANY47.55%225 859
JOHNSON & JOHNSON0.44%416 161
ROCHE HOLDING AG18.38%343 323
PFIZER, INC.48.55%306 912
NOVO NORDISK A/S66.91%247 444
ABBVIE INC.8.18%204 915